Pharmaceutical company Evolus has announced the launch of injectable hyaluronic acid (HA) gel collection Estyme in Europe.
The company shares that the collection features four injectable HA gels; the debut of Estyme Lips and Estyme Sculpt, accompanied by Estyme Smooth and Estyme Form, which are currently marketed in the US under the brand name Evolysse.
Evolus explains that the gels cover a wide range of applications, including preserving the natural structure of the HA molecule, aiming to provide long-lasting, natural-looking results.
David Moatazedi, president and chief executive officer of Evolus, commented, “We are especially excited to introduce Estyme Sculpt to practitioners, a product we believe has the potential to become a leader in mid-face volumising treatments. By pairing this innovative technology with the commercial strength we’ve built with Nuceiva, we are uniquely positioned among several companies with a neurotoxin and filler portfolio.”